文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

维洛贝利单抗治疗COVID-19的疗效异质性:一项随机对照试验的二次分析

Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.
PubMed 文献 · Crit Care · 2024-06-28
一句话结论在机械通气的COVID-19患者中,维洛贝利单抗的28天死亡率获益在δ型脓毒症亚型中可能更明显(OR=0.17),但整体疗效异质性有限。

该研究为PANAMO试验(NCT04333420)的事后二次分析,纳入368例机械通气的COVID-19患者,旨在通过无监督学习探索维洛贝利单抗疗效的异质性。采用潜在类别分析(LCA)、Ward层次聚类(HC)及预先描述的临床脓毒症表型进行分型。主要终点为28天死亡率。LCA模型中,82例(22%)归为类别1(病情更重、死亡率更高),286例(78%)归为类别2;调整逻辑回归未观察到类别间疗效异质性(p=0.998)。HC未发现显著类别(p=0.669)。在临床脓毒症亚型中,41例(11%)为α型、17例(5%)为β型、112例(30%)为δ型、198例(54%)为γ型;亚型间存在疗效异质性(p=0.001),δ型接受维洛贝利单抗后28天死亡率改善(OR=0.17,95% CI 0.07-0.40,p<0.001)。各亚型均未观察到维洛贝利单抗治疗有害信号。总体而言,除δ型外,疗效在不同类别和亚型间一致,提示对最重症患者可能有额外获益。

要点

  • 在368例机械通气的COVID-19患者中,维洛贝利单抗的28天死亡率获益在δ型脓毒症亚型中更明显(OR=0.17,95% CI 0.07-0.40,p<0.001)。
  • 潜在类别分析(LCA)将患者分为类别1(82例,22%,病情更重、死亡率更高)和类别2(286例,78%),调整逻辑回归未显示类别间疗效异质性(p=0.998)。
  • Ward层次聚类(HC)未发现显著类别(p=0.669)。
  • 临床脓毒症亚型分布:α型41例(11%)、β型17例(5%)、δ型112例(30%)、γ型198例(54%);亚型间疗效异质性显著(p=0.001)。
  • 各临床亚型中均未观察到维洛贝利单抗的治疗有害信号。

适用人群与场景

  • 机械通气的COVID-19患者(PANAMO试验纳入人群)。

研究设计与关键结果

  • 研究类型:随机对照试验的事后二次分析;样本量368例;人群为机械通气的COVID-19患者;干预为维洛贝利单抗(C5a抑制剂)对比对照;主要终点为28天死亡率。
  • LCA模型:82例(22%)归为类别1(病情更重、死亡率更高),286例(78%)归为类别2;调整逻辑回归未观察到类别间疗效异质性(p=0.998)。
  • Ward层次聚类:未发现显著类别(p=0.669)。
  • 临床脓毒症亚型:α型41例(11%)、β型17例(5%)、δ型112例(30%)、γ型198例(54%);亚型间存在疗效异质性(p=0.001);δ型接受维洛贝利单抗后28天死亡率改善(OR=0.17,95% CI 0.07-0.40,p<0.001)。
  • 各临床亚型中均未观察到维洛贝利单抗的治疗有害信号。

证据类型、等级与局限

  • 证据类型:随机对照试验的事后二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,除δ型亚型外,维洛贝利单抗的疗效在不同类别和亚型间一致;δ型亚型(最重症患者)可能从维洛贝利单抗治疗中获得额外获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

In a phase 3 trial (PANAMO, NCT04333420), vilobelimab, a complement 5a (C5a) inhibitor, reduced 28-day mortality in mechanically ventilated COVID-19 patients. This post hoc analysis of 368 patients aimed to explore treatment heterogeneity through unsupervised learning. All available clinical variables at baseline were used as input. Treatment heterogeneity was assessed using latent class analysis (LCA), Ward's hierarchical clustering (HC) and the adjudication to previously described clinical sepsis phenotypes. The primary outcome was 28-day mortality. For LCA, a 2-class latent model was deemed most suitable. In the LCA model, 82 (22%) patients were assigned to class 1 and 286 (78%) to class 2. Class 1 was defined by more severely ill patients with significantly higher mortality. In an adjusted logistic regression, no heterogeneity of treatment effect (HTE) between classes was observed (p = 0.998). For HC, no significant classes were found (p = 0.669). Using the previously described clinical sepsis subtypes, 41 patients (11%) were adjudicated subtype alpha (α), 17 (5%) beta (β), 112 (30%) delta (δ) and 198 (54%) gamma (γ). HTE was observed between clinical subtypes (p = 0.001) with improved 28-day mortality after treatment with vilobelimab for the δ subtype (OR = 0.17, 95% CI 0.07-0.40, p < 0.001). No signal for harm of treatment with vilobelimab was observed in any class or clinical subtype. Overall, treatment effect with vilobelimab was consistent across different classes and subtypes, except for the δ subtype, suggesting potential additional benefit for the most severely ill patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. van Amstel RBE, Slim MA, Lim EHT, et al. Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial. Crit Care. 2024. PMID: 38943192. doi:10.1186/s13054-024-05004-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。